Lysopin | 34522-31-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Lysopin
• 英文别名: 6-azaniumyl-2-(1-carboxylatoethylazaniumyl)hexanoate
• CAS: 34522-31-1
• 化学式: C₉H₁₈N₂O₄
• mdl: MFCD24392756
• 分子量: 218.253
• InChiKey: ZZYYVZYAZCMNPG-UHFFFAOYSA-N

物化性质

• 沸点：
  424.1±45.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)
• 物理描述：
  Solid
• 熔点：
  240°C

计算性质

• 辛醇/水分配系数(LogP)：
  -5
• 重原子数：
  15
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.777
• 拓扑面积：
  113
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• AMINO ACID AMIDES OF PHENOXYBUTYRIC ACID DERIVATIVES
  申请人：LALEZARI IRAJ

  公开号：US20120232120A1

  公开（公告）日：2012-09-13

  A compound of the formula: where X is phenyl substituted at the 3, 4 and 5 positions with R1, R2 or R3 which are selected from hydrogen, chloro, lower alkyl of 1 to 5 carbons, phenoxy, phenyl, naphthyl, or phenyl (lower) alkyl where the lower alkyl group has 1-5 carbon atoms and m is 0 or 1; Y is —CONH— or —NHCONH— where the nitrogen atoms are unsubstituted or substituted with other phenoxyisobutyric acid derivatives, or the residue of a phenoxyisobutyric acid and n is 0 or 1; Z is unsubstituted phenyl when m is 1 and n is 1; when Y is 0, X is 0; Z is also substituted.

  式的化合物： 其中X是苯基，取代在3、4和5位与R1、R2或R3，它们从氢、氯、1至5个碳原子的低烷基、苯氧基、苯基、萘基或苯基（低）烷基中选择，其中低烷基基团有1-5个碳原子，m为0或1；Y为—CONH—或—NHCONH—，其中氮原子未取代或取代为其他苯氧异丁酸衍生物，或苯氧异丁酸的残基，n为0或1；当m为1且n为1时，Z为未取代的苯基；当Y为0时，X为0；Z也被取代。
• [EN] TLR-AGONIST-CONJUGATED ANTIBODY RECRUITING MOLECULES (TLR_ARMS)<br/>[FR] MOLÉCULES DE RECRUTEMENT D'ANTICORPS CONJUGUÉS À UN AGONISTE DE TLR)
  申请人：UNIV YALE

  公开号：WO2013166110A1

  公开（公告）日：2013-11-07

  The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) and Toll-like receptor agonist (TLR) through a linker and a multifunctional connector group or molecule.

  本发明涉及嵌合化学化合物，用于招募抗体到癌细胞，特别是前列腺癌细胞或转移的前列腺癌细胞。根据本发明的化合物包括一个与细胞结合末端（CBT）和通过连接物和多功能连接组或分子共价结合的抗体结合末端（ABT）基团和Toll样受体激动剂（TLR）。
• [EN] SMALL MOLECULE BASED ANTIBODY-RECRUITING COMPOUNDS FOR CANCER TREATMENT<br/>[FR] COMPOSÉS DE RECRUTEMENT D'ANTICORPS À BASE DE PETITES MOLÉCULES POUR LE TRAITEMENT DU CANCER
  申请人：UNIV YALE

  公开号：WO2017023994A1

  公开（公告）日：2017-02-09

  The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds bind to the urokinase-type plasminogen activator receptor (uPAR) on the surface of a cancer cell, including a metastatic cancer cell, and consequently recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) against a large number and variety of cancers, thus providing cancer cell death and an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.

  本发明涉及嵌合（包括双功能）化合物，包含这些化合物的组合物以及治疗患者或受试者癌症的方法，特别是包括转移性癌症，其中癌细胞相对于正常（非癌细胞）细胞表现出细胞表面尿激酶型纤溶酶原激活剂受体（尿激酶受体）的过表达（增强表达）。这些化合物与癌细胞表面的尿激酶型纤溶酶原激活剂受体（uPAR）结合，包括转移性癌细胞，从而招募患者或受试者的天然抗体，这些抗体可以通过抗体依赖性细胞吞噬和抗体依赖性细胞毒性（ADCC）和/或补体依赖性细胞毒性（CDC）选择性地降解和/或使靶向的癌细胞失活，针对大量和各种癌症，从而提供癌细胞死亡并抑制癌症的生长、扩散和/或转移，包括患者癌症的缓解和治愈。
• [EN] BIFUNCTIONAL ANTIFUNGAL AGENTS AND METHODS OF TREATING FUNGAL INFECTION<br/>[FR] AGENTS ANTIFONGIQUES BIFONCTIONNELS ET PROCÉDÉS DE TRAITEMENT D'UNE INFECTION FONGIQUE
  申请人：UNIV YALE

  公开号：WO2018035424A1

  公开（公告）日：2018-02-22

  The present invention is directed to bifunctional compounds which are useful in the treatment of fungal infections. The present compounds contains at least one fungal binding moiety (FBM) which is linked to at least one antibody binding moiety (ΑBΜ or ABT group) through a linker group, which optionally comprises a connector group. Compounds accordirig to the present invention are useful in the treatment of fungal infections as described herein.

  本发明涉及一种用于治疗真菌感染的双功能化合物。这些化合物至少包含一个真菌结合基团（FBM），该基团通过连接器基团链接到至少一个抗体结合基团（ΑBΜ或ABT基团），该连接器基团可选地包含连接器基团。根据本发明的化合物可用于治疗如本文所述的真菌感染。
• [EN] ADVANCED GLYCATION END-PRODUCT BREAKING BIOCATALYSTS<br/>[FR] BIOCATALYSEURS DE RUPTURE DE PRODUITS FINAUX DE GLYCATION AVANCÉE
  申请人：UNIV YALE

  公开号：WO2020215043A1

  公开（公告）日：2020-10-22

  In various aspects and embodiments the invention provides compositions and methods for removing glucosepane from one or more proteins in a subject. In certain embodiments, the method comprises administering to the subject an effective amount of a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-13, or a biologically active fragment thereof.

  在各个方面和实施方式中，该发明提供了用于从受体中的一个或多个蛋白质中去除葡萄糖胺的组合物和方法。在某些实施方式中，该方法包括向受体施用包含从以下序列中选择的氨基酸序列的多肽的有效量，该序列包括SEQ ID NOs: 1-13，或其生物活性片段。